Inventio brings novel intellectual property to established market leaders to advance industry applications for the improvement of performance. IP is carefully curated for legally appropriate registration and maintenance. Inventio offers its inventions for licensing by territory or a complete divestiture of inventions as its core activity.

Global company providing newly patented, residual sanitizer and disinfectant products for hard surfaces and hand disinfection. The platform uses 80% less active chemical ingredient than conventional disinfectant products creating an attractive ESG profile. The robust pipeline ranges from Development proof of concept through to Regulatory approvals to ensure at least a decade of steady product releases. Todd led the start-up company through an international acquisition during the pandemic, a strategic pivot to new EPA Residual (RSS) performance claim and has positioned the company to enter multi-national manufacturing, distributor sales, retail sales partnerships and licensing arrangements. The product pipeline spans multiple application methods (wipes, mists, aerosols) with advancements of company technology that promotes longer lasting and more powerful pathogen killing solutions. The chemical technology platform of the company provides for applications on hard surface as well as in pharmaceutical and soft good uses. Todd's background in global logistics, supply chain strategy, regulatory disciplines and multi-national commercial projection has enabled the construct of a seasoned team of veteran industry operators and a strategy poised to disrupt and materially advance the need for lasting innovation that defeat resistant pathogens.

Former Commercial leader for PwC’s human body simulation model, Bodylogical, within PwC’s DoubleJump Health unit. Brought PwC's time based simulation platform of the human body's physiology for health and disease modeling to risk based entities (insurers, employers) delivering true population health management innovation and to the Pharma Life Sciences industry for clinical trial simulation and therapy design simulation. Simulation also focused patient health and condition management to project health status changes from incorporating incremental change strategies. This differential equation based model of human physiology stood apart from AI and machine learning platforms through complex capabilities that have achieved scientific and clinical community recognition for accuracy. Previously, a strategy lead in the Pharma Life Science commercial practice within the Health Industries Advisory practice. Innovator of New Health Economy program. Developed a portfolio for product companies to achieve Strategic Account commercialization with designs that converted Sales Forces from reach and frequency models to lean, highly skilled KAM teams with reduced costs and impactful execution. Past specialties include managed care strategies, specialty drug channel strategies, patient specialty disease management programs, employer group sales strategies, ACO/ population health and digital telehealth enablement. Supply chain synchronization and international trade management practice delivery across multiple industries.Speech personality for PwC and an original author of the Pharma 2020 Series, The Next President and a leading Affordable Care Act expert. Published Thought Leader with public press interview experience. Industry Focus: pharmaceutical, biotechnology, medical device, med-surg. Disciplines: Go to Market Transformation, S&OP, SKU rationalization, Profitability Improvement, Restructuring, Post-merger Integration, Supply chain Strategy; Product launch

Launched and led a boutique consulting team specialized as a leading innovator in the Specialty drug and Specialty pharmacy segments. Positioned drug products in the U.S. market across 19 therapeutic areas. Strategically consulted biotech, big pharma, med-surg, big three wholesalers and distributors, and delivered specialty pharmacy strategies for the largest pharmacy networks in the U.S. Developed activity based costing for fee for service models in specialty pharmacies to meet fair market value transparency tests. Drove 3X growth for three top 10 biotech products through channel strategy launch and redesign programs. Achieved industry acknowledgement as leading practioners in the Specialty drug marketplace.• Specialty Pharmacy Business Strategy – $32 plus Billion National Retail Pharmacy Company. Led project team to deliver a business strategy that analyzed payer environment, manufacturer environment, new value propositions, financial pro formas and the means of implementation to realize strategy.• Specialty Pharmacy Channel Strategy and Design – $10 plus Billion Biotechnology Manufacturer. Led a project team to develop a business strategy that evaluated specialty pharmacy provider (SPP) market, SPP trading environment, acquisition of an SPP, SPP start-up and channel relevance versus other pharmacy sectors.• U.S. Healthcare Distributor Contracting Strategy – U.S. Healthcare Medical-Surgical Products, $150B Manufacturer. Structured contract model for company to formally contract trading intermediaries and Distributors which included: service level agreement; subsidiary/operating company rider agreements; differentiated status levels for distributors with incentives; a conversion from cost-plus product value compensation to fee-for-service value-based compensation; secondary market prevention and measurement devices; and a formalization of trading terms with bilateral transparency and comprehensive legal protections.

Specialized in corporate restructuring and supply chain strategy. Focused on Pharmaceuticals, Biotechs, Medical Device, Aerospace, Energy and Automotive industries. Led Logistics area of Supply Chain Strategy team nationally.• U.S. Healthcare Go-To-Market Channel Restructuring Strategy, Distribution Logistics Network Cost-To-Serve – U.S. Medical-Surgical Manufacturer $30+B. Managed and executed a strategy project that studied the value proposition of a restructured value chain to the medical-surgical healthcare market including a dimensioning and cost-to-serve projection by channel. Supply chain improvements were modeled and distribution was restructured to reflect both service and cost improvements. Big 3 distributor networks, operations and trading terms of business were analyzed and incorporated along with the practices of major IDNs, GPOs and large hospital networks.• Logistics Network Strategic Redesign – U.S. Healthcare (Medical/Surgical) Products, $17B Manufacturer. Reviewed, restructured and strategically refocused role of logistics within broad context of Supply Chain redesign and revised go-to-market strategy. Rationalized network (-85%), improved inventory velocity (+76%) and reduced logistics cost intensity (55%) through redesigned strategic approach. Enabled conversion of logistics services from a cost center without competitive value to that a value creation vehicle that spawned increased growth in key market segments and which mitigated margin erosion during channel shifts. Utilized activity based costing, CAPS network analysis and 3PL-sourcing strategies for cost justification, cost-to-serve projections by channel and to facilitate program implementation.

Conceived of, proposed and launched a value-added logistics provider business in the Europe, Middle East and Africa world region. Pioneered pan-European logistics consolidation with value added services that enabled mass vendor management for JIT line management, centralized distribution across Europe from multi-model global transport feeds, tax advantaged supply chain strategies and aggressive reductions in customer working capital to drive financial improvement. Tax and supply chain innovations facilitated as catalysts for legal entity restructurings across Europe thereby reducing redundant back office expense and creating natural commercial market regions. These operations, offerings and scaling became a driver for the company's >$1B sale in a global liquidity transaction.

Pioneered the national account strategy for a powerful and privately owned telecommunications business focused upon paging (numeric, alpha-numeric) and mobile phone service technology. Focused growth strategies upon mobililty intensive (medical care, emergency services, airlines, service networks, local gov't services) and real time dependent industries (financial services). Growth was over 300% of expectation in first years.